Article

Oncologist Richard T. Silver on Receiving the MPN Hero Award

Richard Silver, an oncologist focused on rare blood diseases called myeloproliferative neoplasms was named an MPN Hero for Commitment to the Broader MPN Community for 2014.

Richard Silver, who was named an MPN Hero at this year's event, is an oncologist and professor of medicine and Director Emeritus of the Richard T. Silver, M.D. Myeloproliferative Neoplasm Center in New York City. He is an attending physician at New York Presbyterian Hospital and medical director of The Cancer Research and Treatment Fund, Inc. Silver was named an MPN Hero for Commitment to the Broader MPN Community.

Silver has written four books and more than 275 peer-reviewed articles, has been the principal investigator in multiple clinical trials, sponsored bi-annual patient-hematologist seminars, is the co-inventor of the BMB biopsy technique, and was instrumental in founding the MPN Center for Research and Therapy. In recognition of his work, patients and colleagues established The Richard T. Silver Distinguished Professor of Hematology/Oncology Chair and Visiting Professorship in the Department of Medicine.

You can learn more about the MPN Heroes at curetoday.com/events/mpn.

Related Videos
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Image of woman with black hair.
Image of man with black hair.
Related Content